Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.
Their new discovery is detailed in the paper titled "Design of novel and highly selective SARS-CoV-2 main protease inhibitors," published in the journal Antimicrobial Agents and Chemotherapy. Despite ...